There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The efficacy of the treatment with Certifect ® (containing fipronil 6.26% w/v, amitraz 7.48% w/v, (S)-methoprene 5.63% w/v) applied topically was assessed in 18 dogs diagnosed with clinical generalized demodicosis. Three treatment regimens were compared over a 3-month period. Starting at Day 0, dogs were treated monthly (group 1) or every two weeks (group 2) with the combination of fipronil, amitraz, and (S)-methoprene or with monthly topical applications of the combination of amitraz and metaflumizone (group 3, reference treatment). Clinical examinations including deep skin scrapings were performed every month in order to evaluate the resolution of clinical signs and the reduction in mite counts. On Day 84, the percentage reduction of mite counts in group 1 was 99.8%, whereas no Demodex canis could be detected in groups 2 and 3 (i.e. 100% parasitological efficacy). As a result of the Demodex mite count reduction, the skin condition of the dogs improved significantly in all groups. This study illustrates, that both monthly and bi-weekly treatments with Certifect were effective in treating dogs with generalized demodicosis over a 3-month period.

Related collections

Most cited references 10

Record: found
Abstract: found
Article: not found

Small Demodex populations colonize most parts of the skin of healthy dogs.

Laura Altet, Mar Bardagí, Wendy Roldán … (2013)

It is unproven that all dogs harbour Demodex mites in their skin. In fact, several microscopic studies have failed to demonstrate mites in healthy dogs. Demodex canis is a normal inhabitant of the skin of most, if not all, dogs. This hypothesis was tested using a sensitive real-time PCR to detect Demodex DNA in the skin of dogs. One hundred dogs living in a humane society shelter, 20 privately owned and healthy dogs and eight dogs receiving immunosuppressive or antineoplastic therapy. Hair samples (250-300 hairs with their hair bulbs) were taken from five or 20 skin locations. A real-time PCR that amplifies a 166 bp sequence of the D. canis chitin synthase gene was used. The percentage of positive dogs increased with the number of sampling points. When a large canine population was sampled at five cutaneous locations, 18% of dogs were positive for Demodex DNA. When 20 skin locations were sampled, all dogs tested positive for mite DNA. Our study indicates that Demodex colonization of the skin is present in all dogs, independent of age, sex, breed or coat. Nevertheless, the population of mites in a healthy dog appears to be small. Demodex DNA was amplified from all 20 cutaneous points investigated, without statistically significant differences. Using a real-time PCR technique, Demodex mites, albeit in very low numbers, were found to be normal inhabitants of haired areas of the skin of healthy dogs. © 2013 The Authors. Veterinary Dermatology © 2013 ESVD and ACVD.

0 comments Cited 12 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare).

Ralf Mueller, Daniela Meyer, Emmanuel Bensignor … (2009)

In this multicentre study, the efficacy of a spot-on formulation containing 10% imidacloprid and 2.5% moxidectin (Advocate, Bayer HealthCare) was evaluated for the treatment of dogs with generalized demodicosis. The spot-on was applied every 2 weeks. Secondary bacterial infections were diagnosed by clinical examination, cytology and bacterial culture as appropriate and treated with oral antibiotics. Improvement or deterioration was determined monthly by clinical scores and by assessing mite numbers on microscopy of skin scrapings. Seventy-two dogs were included in the study. Fifty-two dogs had juvenile-onset demodicosis (mean of 11 months, range 2-24 months) and 20 dogs were adults at onset of disease (mean of 8.6 years, range 3.5-14 years). Twenty-six dogs went into remission, three with adult-onset demodicosis, 23 with juvenile-onset. The latter group showed significantly higher remission rates (P = 0.0252). Time until remission varied from 4 to 32 weeks (mean of 12.5 weeks). Dogs with a clinical score of 45 went into remission. Adverse effects were not observed. One of the dogs responding to treatment showed recurrence of the disease during a follow-up period of 12 months. This study shows a better success rate of Advocate in dogs with mild clinical signs, versus those with moderate to severe clinical signs.

0 comments Cited 11 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study.

K Hellmann, P Dumont, K Krieger … (2005)

Efficacy and safety of the test product imidacloprid 10%+moxidectin 2.5% spot on (Advocate, Advantage multi) in the treatment of canine generalized demodicosis were evaluated in a multi-centre, controlled, randomized, blinded field study in Albania, France, and Germany. The study was conducted according to a non-inferiority design to demonstrate that the efficacy of the test product is not inferior to that of a control product containing milbemycin oxime (Interceptor, tablets for oral application). Of the 72 dogs enrolled, all of which expressed clinical signs of generalized demodicosis, 63 completed the study. Of these, 30 dogs were treated 2-4 times, at 4-week intervals, with the test product at the recommended dose of at least 0.1 ml/kg body weight. Thirty-three dogs were treated daily for two to four periods of 4 weeks with the control product according to label instructions (0.5-1 or 1-2 mg/kg body weight). Presence of mites in deep skin scrapings and clinical improvement were assessed 3-6 times at each inspection at 4-week intervals. Treatment was discontinued in dogs negative for mites on two subsequent examinations 4 weeks apart or at the last examination on day 84. At the end of the trial, dogs in both groups showed a similar clinical improvement. No Demodex mites were detected in 26 of 30 dogs treated with imidacloprid/moxidectin and in 29 of 33 dogs treated with milbemycin oxime. Statistical evaluation confirmed that the efficacy of the test product in the treatment of generalized canine demodicosis was not inferior to that of milbemycin oxime.

0 comments Cited 11 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

PMC ID:: 3834659

DOI:: 10.1051/parasite/2013046

License:

http://creativecommons.org/licenses/by/2.0

Keywords: demodex canis,demodicosis,treatment,fipronil/amitraz/(s)-methoprene,dog

Data availability:

Keywords: demodex canis, demodicosis, treatment, fipronil/amitraz/(s)-methoprene, dog

Efficacy of a topical application of Certifect® (fipronil 6.26% w/v, amitraz 7.48% w/v, (S)-methoprene 5.63% w/v) for the treatment of canine generalized demodicosis

Read this article at

Abstract

Related collections

Parasite

Most cited references 10

Small Demodex populations colonize most parts of the skin of healthy dogs.

Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare).

Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study.

Author and article information

Journal

Comments

Comment on this article

Similar content 298

Cited by 6

Most referenced authors 62